PharmaCyte Biotech, Inc. filings document the company's public-company reporting, capital structure and governance as a Nasdaq-listed biotechnology issuer with common stock registered under PMCB. Recent disclosures include 8-K material-event reports, proxy statements for stockholder votes, equity incentive plan amendments, securities issuance authorizations, preferred stock and warrant financing terms, and notices related to periodic reporting.
The filings also document material agreements tied to external investments and capital deployment, alongside shareholder voting mechanics and security-structure disclosures for common stock, convertible preferred stock and warrants.
PharmaCyte Biotech, Inc. (PMCB) dismissed CBIZ CPAs P.C. and engaged Grassi & Co., CPAs, P.C. as its independent registered public accounting firm, both effective October 14, 2026. Grassi will audit the consolidated financial statements for the fiscal year ending April 30, 2027, and review interim statements beginning with the quarter ending October 31, 2026.
PharmaCyte reported no disagreements with CBIZ during the fiscal years ended April 30, 2026 and 2025, or the subsequent interim period through October 14, 2026. CBIZ’s reports contained no adverse or disclaimer opinion and were not qualified or modified. The company identified previously disclosed material weaknesses in internal control over financial reporting involving insufficient segregation of the Chief Financial Officer’s duties and insufficient management review controls; these were the only reportable events identified for those periods.
PharmaCyte Biotech, Inc. (PMCB) reported no revenue and a net loss attributable to common stockholders of $5.8 million (loss per share $0.54) for the three months ended July 31, 2026, an improvement from an $8.4 million loss ( $1.23 per share) a year earlier, driven largely by changes in fair values of investments and warrant-related liabilities. Operating expenses remained modest for a biotech, with $60,000 in R&D and $946,708 in G&A.
Total assets fell to $36.7 million from $46.8 million, mainly from declines in the fair value of the Q/C Technologies (QCLS) preferred stock and warrants, which generated combined noncash losses of about $8.7 million, and Femasys positions. Cash and cash equivalents were $17.7 million, and management expects roughly $17 million of cash at filing to fund operations for at least 12 months, but additional capital will be needed to complete a pancreatic cancer trial. The FDA’s clinical hold on the LAPC program remains in place while extensive preclinical, manufacturing, and device-compatibility work continues, and a Business Review Committee has curtailed program spending amid dependence on SG Austria. PMCB also remains out of compliance with Nasdaq’s $1.00 minimum bid price and has shareholder approval for a potential reverse stock split to regain compliance.
PharmaCyte Biotech, Inc. is a Nevada-based, development-stage biotechnology company developing cellular therapies for cancer using its cellulose-based Cell-in-a-Box encapsulation platform; its current product candidate, CypCaps, targets locally advanced, inoperable, non-metastatic pancreatic cancer.
The lead LAPC program remains under an FDA clinical hold on a 2020 Investigational New Drug application. Regulators requested extensive additional nonclinical, manufacturing and device-compatibility work. PharmaCyte and its partners report completing key stability, genetic-sequencing, biocompatibility and toxicity studies, while other mechanical and delivery-system tests continue, alongside active dialogue with the FDA.
Strategic risk is high. All licensed patents on the core technology have expired, know-how resides with SG Austria, and the board has curtailed development spending while a Scientific Committee reassesses programs and the SG Austria relationship. Austrianova is the sole manufacturer and has experienced supply-chain delays and possible liquidity constraints. The company had two employees as of April 30, 2026, relies heavily on consultants, holds orphan drug status for its pancreatic cancer therapy, and reported $6,278,282 in non-affiliate equity market value and 10,735,649 common shares outstanding.
WALKER WAYNE REMELL reported acquisition or exercise transactions in this Form 4 filing.
PharmaCyte Biotech, Inc. director Wayne Remell Walker reported an administrative correction to a prior stock option grant. The footnote explains that the grant was made in error and has been cancelled, leaving 0.0000 derivative securities from this grant and no common stock bought or sold.
Abecassis Michael M reported acquisition or exercise transactions in this Form 4 filing.
PharmaCyte Biotech, Inc. director Michael M. Abecassis reported an amended insider transaction dated 2026-03-31 involving a stock option classified as a derivative security.
The amendment states the previously reported grant was made in error and has been cancelled, with 0.0000 shares and 0.0000 derivative holdings shown after this correction.
SCHECHTER JONATHAN reported acquisition or exercise transactions in this Form 4 filing.
PharmaCyte Biotech director Jonathan Schechter filed an amended insider report for a stock option (right to buy) entry dated March 31, 2026. A footnote explains that the reported grant was made in error and has been cancelled, leaving 0 options from this grant outstanding.
WEINSTEIN ROBERT reported acquisition or exercise transactions in this Form 4 filing.
PharmaCyte Biotech, Inc. director Robert Weinstein reported a correction to a stock option award. A previously reported Stock Option (Right to Buy) grant dated 2026-03-31 was made in error and has been cancelled, leaving 0 derivative shares transacted and 0 shares remaining from that specific grant.
PharmaCyte Biotech, Inc. reported that director Robert Weinstein received a grant of stock options covering 119,170 shares of common stock. The options have an exercise price of $0.67 per share, were awarded at no cost, and expire on March 30, 2036. They will vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service.
PharmaCyte Biotech, Inc. director Wayne Remell Walker received a grant of stock options covering 119,170 shares of common stock. The options have an exercise price of $0.67 per share and expire on March 30, 2036, with 119,170 derivative securities held after this grant.
According to the filing, the options will vest in full on the date of the company’s next annual meeting of stockholders, subject to Mr. Walker’s continued service. This award is characterized as a grant or other acquisition of derivative securities rather than an open-market purchase.
PharmaCyte Biotech director Jonathan Schechter received a grant of stock options for 119,170 shares of Common Stock. The options have a $0.67 exercise price, expire on March 30, 2036, and were awarded as compensation, not an open-market purchase. They vest in full at the issuer's next annual stockholder meeting, subject to his continued service, leaving him with 119,170 options following this grant.